ResMed Inc.

NYSE:RMD

Medical - Devices

Healthcare
$242.61 +0.85%

+$1.58 today

Market cap
$34.12B
Beta
0.78
P/E (TTM)
18.1
EPS (TTM)
$10.37
Dividend yield
1.28%
52W Low $180.27High $293.81

Volume 1.22M

Average 1.32M

RMD Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

ResMed Inc.NYSE: RMD

Stock-Based Compensation · Q4 FY2026 · quarter ended Jun 2026

Stock-based compensation growth accelerates

Q4 FY2026 stock-based compensation of $104.35M rose 321.6% year over year, ahead of the +97.7% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 289.5% from the prior quarter. Over 3 fiscal years it compounded at +13.6% a year.

Context

  • Stock-based compensation amounted to 1.8% of revenue in FY2026, unchanged from a year earlier.
  • Stock-based compensation increased in 3 of the last 3 fiscal years.
  • FY2026 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +321.6% holds above the trailing-twelve-month pace of +97.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$104.35M+289.5% QoQ
Last fiscal yearJun 2026
$104.35M+13.8% YoY
LTMJun 2026
$181.24M+97.7% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+321.6%——
1 year+13.8%——
3-year CAGR+13.6%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2026
104.35M USD
Year-over-year change
+13.8%
4-year CAGR
+12.5%

Stock-Based Compensation vs competitors

How RMD compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +97.7% is the highest of 9, against a peer median of -1.3%.
  • Stock-based compensation amounts to 3.2% of revenue for RMD, versus a peer median of 1.1%.
RMD Competitors
Stock-Based Compensation for RMD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ISRGIntuitive Surgical, Inc.LTM Sep 2026$835.3M USD+9.6%+15.4%7.2%
MDTMedtronic plcLTM Jul 2026$496M USD+14.8%+8.8%1.3%
RMDResMed Inc.LTM Jun 2026$181.24M USD+97.7%+13.6%3.2%
BSXBoston Scientific CorporationLTM Jun 2026$166M USD+5.7%+10.8%0.8%
INSPInspire Medical Systems, Inc.LTM Jun 2026$119.43M USD-8.2%+35.8%13.3%
GEHCGE HealthCare Technologies Inc.LTM Jun 2026$118M USD+6.3%+24.7%0.6%
PHGKoninklijke Philips N.V.LTM Jun 2026€112M EUR-17.6%—0.6%
TFXTeleflex IncorporatedLTM Jun 2026$20.21M USD-33.5%—0.8%
ELMDElectromed, Inc.LTM Mar 2026$2.61M USD-8.5%+46.3%3.6%
Peer median (excluding RMD) —-1.3%+20.1%1.1%

Competitors are the stored peer set for RMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
FY2026
Jun 2026
Net Income779.44M897.56M1.02B1.4B1.52B
Depreciation & Amortization193.84M197.56M216.21M235.81M244.15M
Deferred Income Tax0216K000
Stock-Based Compensation65.26M71.14M80.18M91.66M104.35M
Change in Working Capital(708.08M)(462.13M)44.78M16.74M(74.24M)
Accounts Receivables19.35M(106.51M)(134.28M)(76.68M)(96.78M)
Inventory(311.68M)(248.83M)172.2M(80.17M)(9.92M)
Accounts Payables(247.63M)31.34M090.96M172.72M
Other Working Capital(168.11M)(138.13M)6.86M82.63M(140.26M)
Other Non-Cash Items20.69M(11.05M)39.13M6.66M8.28M
Operating Cash Flow351.15M693.3M1.4B1.75B1.81B
Capital Expenditures(156.04M)(134M)(114.86M)(89.87M)(156.29M)
Acquisitions (Net)(42.78M)(1.01B)(133.46M)(139.25M)(350.72M)
Purchases of Investments(20.72M)(32.23M)(22.46M)(6.42M)(28.54M)
Sales of Investments6.8M3.94M1M02.75M
Other Investing Activities(17.18M)15.2M(15.4M)35.48M(12.41M)
Investing Cash Flow(229.92M)(1.16B)(269.78M)(200.05M)(545.2M)
Debt Repayment122M665M(730M)(40M)(10M)
Common Stock Issued47.38M49.14M53.09M74.44M74.5M
Common Stock Repurchased00(150.01M)(300.03M)(700.04M)
Dividends Paid(245.34M)(258.28M)(282.32M)(310.88M)(349.66M)
Other Financing Activities(52.41M)(32.99M)(10.05M)(29.79M)(21.83M)
Financing Cash Flow(128.36M)422.87M(1.12B)(606.25M)(1.01B)
Effect of Forex Changes(14.43M)(2.15M)(1.72M)25.8M6.18M
Net Change in Cash(21.57M)(45.82M)10.47M971.09M259.78M
Free Cash Flow195.11M559.3M1.29B1.66B1.65B

ResMed Inc.

NYSE:RMD

Intrinsic Alpha fair value

Locked

Current Price

$242.61

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.